文献速递脑血管病

降压与他汀治疗用于卒中一级预防:HOPE-3试验的二次分析

Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial.
PubMed 文献 · Stroke · 2021-05-14

HOPE-3试验的二次分析评估了坎地沙坦联合氢氯噻嗪与瑞舒伐他汀对中等心血管风险人群首次卒中的影响。结果显示瑞舒伐他汀10 mg/日显著减少卒中,联合降压治疗使缺血性卒中风险降低59%,两种治疗安全且耐受良好。

要点

  • 瑞舒伐他汀10 mg/日显著降低首次卒中风险(HR 0.70,95%CI 0.52–0.95)。
  • 单纯降压治疗未显著降低卒中风险(HR 0.80,95%CI 0.59–1.08)。

核心结论

  • 在无明确心血管疾病的中等风险人群中,瑞舒伐他汀10 mg/日显著减少首次卒中。
  • 降压联合瑞舒伐他汀使缺血性卒中风险降低59%。

主要发现

  • 随访5.6年共发生169例卒中(117例缺血性,29例出血性,23例原因不明)。
  • 降压治疗未显著降低卒中(HR 0.80,95%CI 0.59–1.08)或缺血性卒中(HR 0.80,95%CI 0.55–1.15)。
  • 瑞舒伐他汀显著降低卒中(HR 0.70,95%CI 0.52–0.95),主要减少缺血性卒中(HR 0.53,95%CI 0.37–0.78)。
  • 联合治疗对比双安慰剂显著降低卒中(HR 0.56,95%CI 0.36–0.87)和缺血性卒中(HR 0.41,95%CI 0.23–0.72)。

关键数值与推荐

  • 基线血压138/82 mm Hg,积极治疗降低6.0/3.0 mm Hg;基线LDL-C 3.3 mmol/L,降低0.90 mmol/L。

临床怎么用

  • 对于中等心血管风险且无明确心血管疾病的人群,可考虑使用瑞舒伐他汀10 mg/日预防首次卒中。
  • 联合降压与瑞舒伐他汀治疗可显著降低缺血性卒中风险,且安全耐受良好。

局限性

  • 本研究为二次分析,卒中事件数较少,亚组分析可能受限。
  • 结果需在更广泛人群中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The HOPE-3 trial (Heart Outcomes Prevention Evaluation–3) found that antihypertensive therapy combined with a statin reduced first stroke among people at intermediate cardiovascular risk. We report secondary analyses of stroke outcomes by stroke subtype, predictors, treatment effects in key subgroups. METHODS: Using a 2-by-2 factorial design, 12 705 participants from 21 countries with vascular risk factors but without overt cardiovascular disease were randomized to candesartan 16 mg plus hydrochlorothiazide 12.5 mg daily or placebo and to rosuvastatin 10 mg daily or placebo. The effect of the interventions on stroke subtypes was assessed. RESULTS: Participants were 66 years old and 46% were women. Baseline blood pressure (138/82 mm Hg) was reduced by 6.0/3.0 mm Hg and LDL-C (low-density lipoprotein cholesterol; 3.3 mmol/L) was reduced by 0.90 mmol/L on active treatment. During 5.6 years of follow-up, 169 strokes occurred (117 ischemic, 29 hemorrhagic, 23 undetermined). Blood pressure lowering did not significantly reduce stroke (hazard ratio [HR], 0.80 [95% CI, 0.59–1.08]), ischemic stroke (HR, 0.80 [95% CI, 0.55–1.15]), hemorrhagic stroke (HR, 0.71 [95% CI, 0.34–1.48]), or strokes of undetermined origin (HR, 0.92 [95% CI, 0.41–2.08]). Rosuvastatin significantly reduced strokes (HR, 0.70 [95% CI, 0.52–0.95]), with reductions mainly in ischemic stroke (HR, 0.53 [95% CI, 0.37–0.78]) but did not significantly affect hemorrhagic (HR, 1.22 [95% CI, 0.59–2.54]) or strokes of undetermined origin (HR, 1.29 [95% CI, 0.57–2.95]). The combination of both interventions compared with double placebo substantially and significantly reduced strokes (HR, 0.56 [95% CI, 0.36–0.87]) and ischemic strokes (HR, 0.41 [95% CI, 0.23–0.72]). CONCLUSIONS: Among people at intermediate cardiovascular risk but without overt cardiovascular disease, rosuvastatin 10 mg daily significantly reduced first stroke. Blood pressure lowering combined with rosuvastatin reduced ischemic stroke by 59%. Both therapies are safe and generally well tolerated. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00468923.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Bosch J, Lonn EM, Dagenais GR, et al. Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke. 2021. PMID: 33985364. doi:10.1161/STROKEAHA.120.030790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。